Solventum Corporation (SOLV) Stock Price, Quote & News

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 651 733 1110

Website: www.solventum.com

Address:

3M Center, Building 275-6W-20 2510 Conway Avenue East St. Paul, Maplewood, United States

bigbulldaddy Jan. 14 at 12:33 AM

$MDXG $RCEL $SOLV $VCEL I don’t think SOLV. We just bought restrata… we don’t need RCEL. Our teams could easily sell it into burn centers though.

0 · Reply

JHR Jan. 8 at 5:53 PM

$RCEL Who is going to acquire $RCEL in late 2026? $SOLV $MDXG $VCEL

0 · Reply

SPYmyQQQ Jan. 6 at 6:10 PM

🎯 Target Hit 🏁 📨 From Dec 18, 2025 🏛️ $SOLV 💵 Entry: $80.8600 ✅ Exit: $82.5257 💰 P/L: +2.06% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

JackDarwin Jan. 6 at 1:18 PM

$SOLV Bullish Engulfing Candletick Pattern. Wait for the confirmation from the next day's candle.

0 · Reply

BillionerOfKing Dec. 27 at 12:48 AM

$SOLV Current Stock Price: $80.45 Contracts to trade: $80 SOLV Jan 16 2026 Call Entry: $0.80 Exit: $1.44 ROI: 80% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Dec. 24 at 8:01 PM

$SOLV makes a bold move in advanced wound care — this one matters. Solventum is buying Acera Surgical for $725M upfront, entering the tissue matrices space and expanding its MedSurg and wound care portfolio — a clear strategic push into higher-value solutions. 🧠 See what this acquisition means for the business 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-teaser-26335&ADID=SYND_STOCKTWITS_TWEET_2_2808854_TEASER_26335

0 · Reply

ZacksResearch Dec. 24 at 7:01 PM

$SOLV acquisition alert! 🏥💼 Solventum's $725M deal for Acera Surgical, with an additional $125M contingent payment, positions them in the fast-growing synthetic tissue matrices market. This move strengthens their MedSurg business and aligns with their transformation plan. Shares dipped 0.3% post-announcement, but SOLV's 7.4% gain over six months outpaces the industry's 2.3% growth — a noteworthy development. Discover the full strategic impact here 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-body-26336&ADID=SYND_STOCKTWITS_TWEET_2_2808854_BODY_26336

0 · Reply

OfficialStocktwitsUser Dec. 24 at 3:40 PM

$SOLV RSI: 32.89, MACD: 0.6526 Vol: 2.17, MA20: 82.72, MA50: 77.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

bigbulldaddy Dec. 13 at 2:05 PM

$SOLV We bought ascera which is cool. Growth potential here. The restructure recently is a very interesting choice. They eliminated a key associate rep role that is responsible for managing the home rental VAC business through case managers. It also helped hospitals not lose expensive rental VAC units (which happens frequently). The clinical role was also eliminated which is another interesting choice with the product being difficult to use at times and needing clinical expertise. SOLV will definitely save money in sales expenditures but it really isn’t clear if this is a good idea. Their acute and post acute roles will have to pick up the slack for the missing roles. There will be balls dropped. Some of those balls will have consequences. They think they helped by making territories slightly smaller but it isn’t significantly different. I’m forecasting a hard Q1 while they try to bounce back from the restructure. Ascera restructure still coming…

0 · Reply

BillionerOfKing Dec. 3 at 3:40 PM

$SOLV Current Stock Price: $85.26 Contracts to trade: $85 SOLV Dec 19 2025 Call Entry: $2.00 Exit: $3.57 ROI: 79% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Solventum Completes Acquisition of Acera Surgical

Dec 17, 2025, 4:05 PM EST - 27 days ago

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

Dec 16, 2025, 4:05 PM EST - 4 weeks ago

Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

Dec 11, 2025, 10:17 PM EST - 4 weeks ago

Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not

Dec 2, 2025, 12:23 PM EST - 6 weeks ago

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 25, 2025, 4:05 PM EST - 7 weeks ago

Solventum to Participate in the 2025 Piper Sandler Healthcare Conference

Nov 20, 2025, 9:00 AM EST - 7 weeks ago

Solventum Announces $1 Billion Share Repurchase Program

Nov 20, 2025, 9:00 AM EST - 7 weeks ago

Solventum Announces Agreement to Acquire Acera Surgical

Nov 12, 2025, 1:51 PM EST - 2 months ago

Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 11, 2025, 9:17 AM EST - 2 months ago

Solventum: A Mixed Q3 Provides Further Support For Our Neutral Stance

Nov 6, 2025, 7:26 PM EST - 2 months ago

Solventum Corporation (SOLV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 2 months ago

Solventum Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:05 PM EST - 2 months ago

Solventum to Participate in the 2025 Stifel Healthcare Conference

Oct 22, 2025, 12:42 PM EDT - 2 months ago

Solventum: A Solid Performance Here

Oct 21, 2025, 5:00 PM EDT - 3 months ago

Solventum Appoints Heather Knight as Chief Commercial Officer

Oct 16, 2025, 4:05 PM EDT - 3 months ago

Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025

Sep 9, 2025, 2:03 PM EDT - 4 months ago

Solventum Corporation (SOLV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 2:30 PM EDT - 4 months ago

Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers

Sep 8, 2025, 8:30 AM EDT - 4 months ago

Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers

Sep 5, 2025, 1:27 PM EDT - 4 months ago

Solventum Corporation (SOLV) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.

TMO

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Thermo Fisher Scientific Completes Acquisition of Solventum's Purification and Filtration Business

TMO

Aug 28, 2025, 4:05 PM EDT - 4 months ago

Solventum to Participate in Upcoming Investor Conferences

Aug 22, 2025, 8:19 AM EDT - 5 months ago

Solventum Announces $1.75 Billion Note Tender Offers

Aug 13, 2025, 10:39 PM EDT - 5 months ago

Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 5 months ago

Solventum Announces Launch of Secondary Offering of Common Stock

Aug 8, 2025, 6:53 AM EDT - 5 months ago

Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:52 PM EDT - 5 months ago

Solventum raises annual profit forecast on strength in surgical equipment

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Solventum Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 9:12 AM EDT - 6 months ago

Solventum: Appealing Again

Jul 17, 2025, 4:05 PM EDT - 6 months ago

Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

Jun 18, 2025, 10:00 AM EDT - 7 months ago

Solventum Named a Best Company to Work for by U.S. News & World Report

Jun 3, 2025, 4:05 PM EDT - 8 months ago

Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

May 11, 2025, 5:07 PM EDT - 8 months ago

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

May 9, 2025, 11:02 AM EDT - 8 months ago

Solventum Corporation: Cheap, With Caveats

May 8, 2025, 6:11 PM EDT - 8 months ago

Solventum beats first-quarter profit estimates on strong surgical product sales

May 8, 2025, 4:05 PM EDT - 8 months ago

Solventum to Participate in the 2025 BofA Securities Health Care Conference

May 8, 2025, 4:05 PM EDT - 8 months ago

Solventum Reports First Quarter 2025 Financial Results

Apr 17, 2025, 4:05 PM EDT - 9 months ago

Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

Mar 25, 2025, 6:00 PM EDT - 10 months ago

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

Mar 21, 2025, 12:44 PM EDT - 10 months ago

3M Spin Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy

Mar 20, 2025, 9:00 AM EDT - 10 months ago

Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day

Mar 12, 2025, 8:12 AM EDT - 10 months ago

Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

Feb 28, 2025, 8:36 AM EST - 11 months ago

Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 5:09 PM EST - 11 months ago

Solventum forecasts annual profit above estimates on strong surgical product sales

Feb 27, 2025, 4:05 PM EST - 11 months ago

Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

Feb 26, 2025, 4:15 PM EST - 11 months ago

Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City

Feb 26, 2025, 3:37 PM EST - 11 months ago

Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports

Feb 26, 2025, 2:50 PM EST - 11 months ago

Trian Comments on Solventum's Sale of its Purification & Filtration Business

TMO

Feb 25, 2025, 10:16 AM EST - 11 months ago

Solventum In The Early Stages Of A Multiyear Turnaround Effort

bigbulldaddy Jan. 14 at 12:33 AM

$MDXG $RCEL $SOLV $VCEL I don’t think SOLV. We just bought restrata… we don’t need RCEL. Our teams could easily sell it into burn centers though.

0 · Reply

JHR Jan. 8 at 5:53 PM

$RCEL Who is going to acquire $RCEL in late 2026? $SOLV $MDXG $VCEL

0 · Reply

SPYmyQQQ Jan. 6 at 6:10 PM

🎯 Target Hit 🏁 📨 From Dec 18, 2025 🏛️ $SOLV 💵 Entry: $80.8600 ✅ Exit: $82.5257 💰 P/L: +2.06% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

JackDarwin Jan. 6 at 1:18 PM

$SOLV Bullish Engulfing Candletick Pattern. Wait for the confirmation from the next day's candle.

0 · Reply

BillionerOfKing Dec. 27 at 12:48 AM

0 · Reply

ZacksResearch Dec. 24 at 8:01 PM

0 · Reply

ZacksResearch Dec. 24 at 7:01 PM

0 · Reply

OfficialStocktwitsUser Dec. 24 at 3:40 PM

0 · Reply

bigbulldaddy Dec. 13 at 2:05 PM

0 · Reply

BillionerOfKing Dec. 3 at 3:40 PM

0 · Reply

JarvisFlow Dec. 2 at 11:05 AM

BTIG has adjusted their stance on Solventum ( $SOLV ), setting the rating to Buy with a target price of 100.

0 · Reply

StockBraker Nov. 28 at 2:07 PM

$SOLV Will buy if it dips to $70 or below.

1 · Reply

MACTEP Nov. 27 at 10:28 AM

$SOLV Doomed. Next target - $75

0 · Reply

danaos Nov. 23 at 11:01 PM

$SOLV Overweight

0 · Reply

ja1234567 Nov. 22 at 3:52 AM

$SOLV quite possibly the stupidest move I have seen in 5 years for any biotech company. Is the a word for overpaid to the point of insanity.

1 · Reply

Boston7452 Nov. 21 at 8:41 PM

$SINT Theres been a scam or really a con going on here but not what youre implying. Tech is game changing and current mgmt is in process of commercializing it. $ZBH $SOLV ?

0 · Reply

prismmarketview Nov. 21 at 2:40 PM

(NYSE: $SOLV) #solventum is buying #acerasurgical for $850M, adding the fast-growing Restrata synthetic wound-care platform to its portfolio and strengthening its position in the $900M acute regenerative tissue market. https://prismmarketview.com/solventum-expands-advanced-wound-care-portfolio-with-850-million-acquisition-of-acera-surgical/

0 · Reply

topstockalerts Nov. 20 at 8:54 PM

Solventum Corp shares rose Thursday after announcing a $1 billion share buyback program and the acquisition of Acera Surgical for up to $850 million. The board approved the open-ended buyback, starting in 2026; Solventum had roughly 173.4 million shares outstanding as of October 31, 2025. The acquisition includes $725 million in cash plus up to $125 million in milestone-based payments. Acera, a regenerative wound-care biotech, expands Solventum’s MedSurg portfolio into synthetic tissue matrices, a $900 million U.S. market. Its Restrata products are currently available in the U.S. for complex wound treatment in acute-care settings. CEO Bryan Hanson highlighted that strong financial performance, cash generation, and a healthy balance sheet allow the company to pursue targeted M&A and return capital to shareholders. $SOLV

0 · Reply

bigbulldaddy Nov. 20 at 2:33 PM

$SOLV Buying restrata here is a decent play. It partners well with veraflo. If we had to buy a skin sub this synthetic is probably the right one. I think this was probably one of the best acquisitions we could make.

0 · Reply

OpenOutcrier Nov. 20 at 2:01 PM

$SOLV (+0.9% pre) Solventum to acquire Acera Surgical for up to $850 million https://ooc.bz/l/85310

0 · Reply

BEATOFtheMARKET Nov. 17 at 2:52 PM

$SOLV $SOYB $SPG $SPHB $SPNS

0 · Reply

BEATOFtheMARKET Nov. 11 at 10:10 PM

$SOLV $SOFI $SNOW $SNDX $SNDK

0 · Reply

Market Cap	14.86B
Revenue (ttm)	8.25B
Net Income (ttm)	478.00M
EPS (ttm)	N/A
PE Ratio	14.50
Forward PE	13.45
Profit Margin	5.79%
Debt to Equity Ratio	1.03

Volume	1,678,200
Avg Vol	1,131,846
Day's Range	N/A - N/A
Shares Out	173.45M
Stochastic %K	23%
Beta	0.34
Analysts	Sell
Price Target	$89.82